Woo, Sungmin http://orcid.org/0000-0001-8459-8369
Freedman, Daniel http://orcid.org/0009-0008-5996-3270
Becker, Anton S. http://orcid.org/0000-0001-8372-6496
Leithner, Doris http://orcid.org/0000-0002-0163-3964
Mayerhoefer, Marius E. http://orcid.org/0000-0001-8786-8686
Friedman, Kent P.
Arita, Yuki http://orcid.org/0000-0002-5285-0352
Han, Sangwon http://orcid.org/0000-0001-8095-0396
Burger, Irene A. http://orcid.org/0000-0001-8029-8692
Taneja, Samir S. http://orcid.org/0000-0003-0887-8259
Wise, David R. http://orcid.org/0000-0003-3419-4723
Zelefsky, Michael J. http://orcid.org/0000-0002-6090-6424
Vargas, Hebert A. http://orcid.org/0000-0003-1169-133X
Article History
Received: 5 February 2024
Accepted: 26 March 2024
First Online: 28 March 2024
Declarations
:
: This study did not involve individual human participant data as it was a systematic review and meta-analysis using only <i>study-level summary data</i> provided openly in the literature. Nevertheless, it was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki, its subsequent amendments, or comparable ethical standards.
: This study did not involve individual human participant data as it was a systematic review and meta-analysis using only <i>study-level summary data</i> provided openly in the literature. As such, the need for informed consent was not applicable.
: MEM received honoraria for lectures from Siemens, GE, and BM but unrelated to the current work. KPF is a co-investigator on “Optimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy” (PI Herbert Lepor) but does not receive any salary support and was unrelated to the current work. IAB has received research support from GE Healthcare and Bayer, speaker honorarium from GE-Healthcare, Baer, Astellas, Janssen and Novartis, and institutionally compensated advisory role for Novartis, Merck & Cie and Ratio Radiotherapeutics but unrelated to the current work. DRW has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer but unrelated to the current work. The other authors have nothing to disclose.